197 related articles for article (PubMed ID: 29545433)
1. Recurrence of eosinophilic oesophagitis with subcutaneous grass pollen immunotherapy.
Wells R; Fox AT; Furman M
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29545433
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.
Wüthrich B; Bucher Ch; Jörg W; Bircher A; Eng P; Schneider Y; Schnyder F; Eigenmann P; Senti G
J Investig Allergol Clin Immunol; 2003; 13(3):145-8. PubMed ID: 14635462
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.
Nelson H; Cartier S; Allen-Ramey F; Lawton S; Calderon MA
J Allergy Clin Immunol Pract; 2015; 3(2):256-266.e3. PubMed ID: 25609326
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
5. Value of microarray allergen assay in the management of eosinophilic oesophagitis.
Armentia A; Martín S; Barrio J; Martín B; García JC; Vega JM; Sánchez A; Fernández P; Corell A
Allergol Immunopathol (Madr); 2015; 43(1):73-80. PubMed ID: 24961955
[TBL] [Abstract][Full Text] [Related]
6. Systemic and large local reactions during subcutaneous grass pollen immunotherapy in children.
Gur Cetinkaya P; Kahveci M; Esenboğa S; Karaatmaca B; Soyer O; Sekerel BE; Tuncer A; Sahiner UM
Pediatr Allergy Immunol; 2020 Aug; 31(6):643-650. PubMed ID: 32320504
[TBL] [Abstract][Full Text] [Related]
7. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass.
Bozek A; Kolodziejczyk K; Krajewska-Wojtys A; Jarzab J
Ann Allergy Asthma Immunol; 2016 Feb; 116(2):156-61. PubMed ID: 26815709
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
9. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of grass pollen-induced allergic rhinitis in specialized current clinical practice in Spain.
Valero A; Chivato T; Justicia JL; Navarro AM;
Allergy Asthma Proc; 2011; 32(5):384-9. PubMed ID: 22195692
[TBL] [Abstract][Full Text] [Related]
11. What Is the Relationship Between Eosinophilic Esophagitis (EoE) and Aeroallergens? Implications for Allergen Immunotherapy.
Egan M; Atkins D
Curr Allergy Asthma Rep; 2018 Jun; 18(8):43. PubMed ID: 29909507
[TBL] [Abstract][Full Text] [Related]
12. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
Dranitsaris G; Ellis AK
J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
[TBL] [Abstract][Full Text] [Related]
13. Adverse Events During Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis - Differences Between Subcutaneous and Sublingual Treatment.
Aasbjerg K; Dalhoff KP; Backer V
Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):73-84. PubMed ID: 25968654
[TBL] [Abstract][Full Text] [Related]
14. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
15. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial.
Shah-Hosseini K; Mioc K; Hadler M; Karagiannis E; Mösges R
Curr Med Res Opin; 2015 Dec; 31(12):2249-59. PubMed ID: 26366617
[TBL] [Abstract][Full Text] [Related]
16. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
17. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
18. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
19. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen.
Martínez-Cañavate Burgos A; Torres-Borrego J; Molina Terán AB; Corzo JL; García BE; Rodríguez Pacheco R; Moreno Aguilar C; Dávila I
Pediatr Allergy Immunol; 2018 Jun; 29(4):369-374. PubMed ID: 29369414
[TBL] [Abstract][Full Text] [Related]
20. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
